Company: LNAI
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001731122-25-001626
Chunk: 9

Company: Lunai Bioworks Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 9
---
Conversion Shares”), based on the stated $0.30 per share conversion price. The
$0.30 per share conversion price of the Convertible Notes represented a premium to the closing price of the Company’s common stock
on July 7, 2025, the date of execution and conversion. As a result of the foregoing transactions, the Company (i) eliminated $9.7 million
of secured indebtedness, (ii) issued $16.1 million in Convertible Notes to the same holders, and (iii) issued 53.6 million shares of common
stock upon full conversion of such Convertible Notes. The transactions did not involve any cash proceeds to the Company.

<div align='center'>S-4</div>

Acquisition of Biosymetrics, Inc.

On April 8, 2025, Lunai completed
the acquisition of Biosymetrics, Inc., a Delaware corporation (“Biosymetrics”), an artificial intelligence (AI)-driven drug
discovery and biomarker identification company, by merger of Renovaro Acquisition Sub, a Delaware corporation and wholly owned subsidiary
of the Company with Biosymetrics, with Biosymetrics as the surviving corporation and a wholly owned subsidiary of Lunai. The Company issued
15.0 million shares of our Common Stock to the former stockholders of Biosymetrics in accordance with the terms of the merger agreement.
Pursuant to the acquisition, the Company gained access to BioSymetrics’ proprietary Elion platform, a cutting-edge AI and machine
learning engine that uncovers complex biological relationships to accelerate the discovery of diagnostics and therapeutics. BioSymetrics’
Phenograph provides a translational engine that maps human clinical signals to prioritized therapeutic targets and is designed to expedite
and improve target and biomarker identification and enable patient stratification and drug repurposing. BioSymetrics’ advanced AI
in vivo modeling and machine vision systems enable high throughput phenotypic screening, leveraging AI-powered analysis to detect subtle
biological responses with unprecedented accuracy. By integrating Elion into Lunai’s workflow, the combined entity aims to streamline
the translation of biomarker insights into accelerated discovery timelines, enhancing precision in target identification and improving
overall research efficiency, ultimately enabling faster and more effective drug discovery and therapeutic development.

Reverse Stock Sp lit

We
filed with the Delaware Secretary
of State a Certificate of Amendment to our Certificate
of Incorporation (the “Certificate of Amendment”)
which became effective at 12:01 a.m.